Early breast cancer treatment patterns study
Part of Cancer, Skin clinical trials.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with invasive breast cancer (cancer that has spread from the milk ducts or lobules into surrounding breast tissue).
- Your tumor size is T1, T2, or T3 (not the largest or most advanced stage).
- You have 0 to 3 lymph nodes under your arm that contain cancer cells.
- Your cancer is estrogen receptor-positive (ER+), meaning it uses the hormone estrogen to grow.
- Your cancer is HER2-negative, meaning it does not have too much of the HER2 protein.
- You have not had chemotherapy before your surgery.
- You have no other cancer in the last 5 years, except for a common skin cancer that was removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.